CN111629757A - 治疗癌症的选择性parp1抑制剂 - Google Patents

治疗癌症的选择性parp1抑制剂 Download PDF

Info

Publication number
CN111629757A
CN111629757A CN201980008960.3A CN201980008960A CN111629757A CN 111629757 A CN111629757 A CN 111629757A CN 201980008960 A CN201980008960 A CN 201980008960A CN 111629757 A CN111629757 A CN 111629757A
Authority
CN
China
Prior art keywords
inhibitor
cancer
use according
parp1
selective inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980008960.3A
Other languages
English (en)
Chinese (zh)
Inventor
M·杜尔
D·里德
乌利亚纳·巴什塔诺瓦
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cambridge Enterprise Ltd
Original Assignee
Cambridge Enterprise Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Enterprise Ltd filed Critical Cambridge Enterprise Ltd
Publication of CN111629757A publication Critical patent/CN111629757A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
CN201980008960.3A 2018-01-17 2019-01-16 治疗癌症的选择性parp1抑制剂 Pending CN111629757A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1800733.6 2018-01-17
GBGB1800733.6A GB201800733D0 (en) 2018-01-17 2018-01-17 Cancer
PCT/GB2019/050110 WO2019141979A1 (en) 2018-01-17 2019-01-16 Selective parp1 inhibitors to treat cancer

Publications (1)

Publication Number Publication Date
CN111629757A true CN111629757A (zh) 2020-09-04

Family

ID=61256175

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980008960.3A Pending CN111629757A (zh) 2018-01-17 2019-01-16 治疗癌症的选择性parp1抑制剂

Country Status (7)

Country Link
US (1) US20210052632A1 (https=)
EP (1) EP3740238A1 (https=)
JP (1) JP7364154B2 (https=)
CN (1) CN111629757A (https=)
CA (1) CA3087652A1 (https=)
GB (1) GB201800733D0 (https=)
WO (1) WO2019141979A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023025307A1 (en) * 2021-08-27 2023-03-02 Impact Therapeutics (Shanghai) , Inc Substituted tricyclic compounds as parp inhibitors and use thereof

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2592555A (en) * 2019-09-27 2021-09-08 Varsity Pharmaceuticals Ltd Cancer
KR20240149429A (ko) * 2022-02-16 2024-10-14 듀크 스트리트 바이오 리미티드 약학적 화합물
IL317573A (en) * 2022-06-15 2025-02-01 Astrazeneca Ab Combination therapy for cancer treatment

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
US20110190390A1 (en) * 2010-01-05 2011-08-04 Nicole Renee Murray Methods and materials for treating pancreatic cancer
WO2015048718A2 (en) * 2013-09-30 2015-04-02 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Inhibition of thymine dna glycosylase in the treatment of cancer
WO2017192740A2 (en) * 2016-05-03 2017-11-09 Galera Labs, Llc Combination therapy for cancer treatment

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2592555A (en) * 2019-09-27 2021-09-08 Varsity Pharmaceuticals Ltd Cancer

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008144067A1 (en) * 2007-05-21 2008-11-27 Board Of Regents, University Of Texas System Methods and compositions for treatment of cancer using oncolytic rsv activity
US20110190390A1 (en) * 2010-01-05 2011-08-04 Nicole Renee Murray Methods and materials for treating pancreatic cancer
WO2015048718A2 (en) * 2013-09-30 2015-04-02 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Inhibition of thymine dna glycosylase in the treatment of cancer
WO2017192740A2 (en) * 2016-05-03 2017-11-09 Galera Labs, Llc Combination therapy for cancer treatment

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
AARON S. MANSFIELD等: "Phase I dose escalation study of the PKCi inhibitor", 《ANTI-CANCER DRUGS》 *
JAMIN D. STEFFEN等: "Structural Implications for Selective Targeting of PARPs", 《FRONTIERS IN ONCOLOGY》 *
MARIANNA TRANI等: "Pro-apoptotic effect of aurothiomalate in prostate cancer cells", 《CELL CYCLE》 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023025307A1 (en) * 2021-08-27 2023-03-02 Impact Therapeutics (Shanghai) , Inc Substituted tricyclic compounds as parp inhibitors and use thereof

Also Published As

Publication number Publication date
US20210052632A1 (en) 2021-02-25
GB201800733D0 (en) 2018-02-28
JP7364154B2 (ja) 2023-10-18
WO2019141979A1 (en) 2019-07-25
CA3087652A1 (en) 2019-07-25
JP2021510677A (ja) 2021-04-30
EP3740238A1 (en) 2020-11-25

Similar Documents

Publication Publication Date Title
JP6763919B2 (ja) Ｄｎａ−ｐｋ阻害剤としての（ｓ）−ｎ−メチル−８−（１−（（２’−メチル−［４，５’−ビピリミジン］−６−イル）アミノ）プロパン−２−イル）キノリン−４−カルボキサミドおよびその重水素化誘導体の共結晶
CN111629757A (zh) 治疗癌症的选择性parp1抑制剂
US20040192656A1 (en) Methods and compositions for the treatment of human and animal cancers
JP2017519019A (ja) ｍｄｍ２阻害剤の間欠投与
EP3697767B1 (en) Compounds and methods for treating cancer
JP2022523672A (ja) がんを治療するための金属キレート化剤併用療法
CA3110609C (en) 5-acetamidomethyl-oxazolidinone derivatives for use in the treatment of cancer
De Waard et al. Inhibition of fibroblast collagen synthesis and proliferation by levamisole and 5-fluorouracil
CN115998872B (zh) 一种含有抑制核酸内切酶功能的药物及其抗肿瘤的用途
Fedorchuk et al. Effectiveness of sodium dichloroacetate against glioma C6 depends on administration schedule and dosage
Roskoski Jr Poly (ADP-ribose) polymerase (PARP) inhibitors approved for the treatment of cancer
US11207319B2 (en) Method for the treatment of bladder cancer
US20220000911A1 (en) Combination of gold complexes with olaparib or other parp1/2 inhibitors for use in the treatment of cancer resistant to said parp1/2 inhibitors
Wang et al. Nutrient transporter-oriented nanoinhibitor counteracts intracellular metabolic reprogramming for RT-resistant HCC treatment
CN101155600B (zh) 放射线治疗增强剂
JP2022541690A (ja) 癌治療のための併用療法
JP2014513698A (ja) がん治療保護のためのヒ素の使用
TW202539682A (zh) 使用parg抑制劑對癌症之治療
Blank et al. Hypericin targets multiple signaling mediators in cancer cells generating unique, diverse anti-tumoral, anti-metastatic, and anti-angiogenic activities with evidence for clinical applicability
CN113456819A (zh) OXPHOS抑制剂作为抗肿瘤药物Alisertib增效剂的应用
CN104302275A (zh) 类固醇反应性皮肤病的治疗方法
HK40031775B (en) Compounds and methods for treating cancer
Ellis et al. Development of Rational Drug Combinations with Investigational Targeted Agents

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication

Application publication date: 20200904

RJ01 Rejection of invention patent application after publication